Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Allogene Therapeutics Inc (ALLO)
NASDAQ:ALLO
RESEARCH TOOLSreports
Holding ALLO?
Track your performance easily
Earnings Data
Report Date
Feb 26, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.33Last Year’s EPS
-$0.51Same Quarter Last Year
Strong Buy
Based on 10 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 07, 2024
|% Change Since: -41.38%
|Next Earnings Date:Feb 26, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted significant advancements in clinical trials for both cancer and autoimmune diseases, showing promising efficacy and strong financial positioning. However, concerns about safety profiles and delays in regimen finalization pose challenges.Company Guidance
During the third quarter of 2024, Allogene Therapeutics provided robust guidance on its ongoing and future clinical endeavors across oncology and autoimmune diseases. The company highlighted the pivotal Phase II ALPHA3 trial for cema-cel in large B-cell lymphoma, aiming to establish the first CAR-T therapy in first-line treatment, with 27 of the planned 50 sites already activated. In solid tumors, the ALLO-316 program for renal cell carcinoma showed a confirmed response rate of 33% and a best overall response rate of 50%, earning RMAT designation from the FDA. The pipeline also includes ALLO-329, targeting autoimmune diseases with Phase I initiation expected in Q1 2025 and proof-of-concept data by year-end, leveraging proprietary Dagger technology to potentially eliminate lymphodepletion. Financially, Allogene ended Q3 with $403.4 million in cash, projecting a cash runway into the second half of 2026, while anticipating a full-year cash burn of approximately $200 million.Progress in ALPHA3 Trial for Large B-Cell Lymphoma
The pivotal Phase II ALPHA3 trial of cema-cel for large B-cell lymphoma is advancing, with 27 of the planned 50 sites activated, including 60% at community centers.
Breakthrough in Solid Tumor Treatment
ALLO-316 showed a confirmed response rate of 33% and best overall response rate of 50% in the Phase I TRAVERSE trial for renal cell carcinoma, earning RMAT designation from the FDA.
Innovative Dual CAR-T Approach for Autoimmune Diseases
ALLO-329, the first dual CD19 CD70 CAR, aims to reduce or eliminate the need for lymphodepleting chemotherapy, with IND filing expected in Q1 2025.
Strong Financial Position
Cash balance of $403.4 million as of Q3 2024, with cash runway extending into the second half of 2026.
---
ALLO Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
ALLO Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 07, 2024 | $3.19 | $3.08 | -3.45% |
| Aug 07, 2024 | $2.47 | $2.36 | -4.45% |
| May 13, 2024 | $2.90 | $2.96 | +2.07% |
| Mar 14, 2024 | $4.50 | $4.66 | +3.56% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Allogene Therapeutics Inc (ALLO) report earnings?
Allogene Therapeutics Inc (ALLO) is schdueled to report earning on Feb 26, 2025, TBA Not Confirmed.
What is Allogene Therapeutics Inc (ALLO) earnings time?
Allogene Therapeutics Inc (ALLO) earnings time is at Feb 26, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ALLO EPS forecast?
ALLO EPS forecast for the fiscal quarter 2024 (Q4) is -$0.33.
---